Cardinal Health, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Providers and Services | Market Cap: ₹46.8K Cr
- Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7). - Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth.
From Cardinal Health, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹199.85
Market Cap
₹46.8K Cr
P/E Ratio
30.6
Revenue Rank
Margin Rank
How does Cardinal Health, Inc. rank in Health Care Providers and Services?
Compare Cardinal Health, Inc. against every Health Care Providers and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7).
- →Continued strong demand and demographic trends support positive outlook in Pharmaceutical and Specialty Solutions segments (Page 4).
- →Growth in other businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics with revenue up 31% and profit up 34% (Pages 3,7).
- →GMPD segment projecting 1% to 3% revenue growth; focus on cost efficiencies and supply chain resilience (Page 4).
- →Positive contribution expected from annualization of Solaris acquisition and synergy realization (Page 4).
- →Ongoing investments in technology and teams targeted for future growth and operational efficiency (Page 7).
- →The company remains confident in long-term EPS growth targets of 12% to 14%, reflecting sustained volume and revenue growth (Pages 6,12).
📈 Profitability & Margins
Rank 3- →Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth.
- →Fiscal 2026 non-GAAP EPS outlook raised to $10.70–$10.80, reflecting 30%–31% annual growth.
- →Segment profit growth in Pharma improved to 22%–23% for fiscal 2026, higher than prior guidance.
- →Continued strong performance in Specialty and other growth businesses, with >20% revenue growth and increased profit guidance.
- →Ongoing operational execution and synergy realization anticipated to support profit improvements.
- →Strategic investments in technology and team aimed at positioning for future growth.
- →Expect robust cash flow generation to support disciplined capital allocation including share repurchases.
- →Monitoring factors like tariffs and macroeconomic impacts, but expect manageable influence.
- →Fiscal 2027 planning underway with positive outlook on demand, demographics, and operational efficiency, detailed guidance to come in Q4 call.
🏗️ Capital Expenditure Plans
Yes- →Investing in infrastructure, technology, and people to improve core Pharma segment, including automation and productivity initiatives in distribution centers.
- →Expansion of at-Home Solutions network capacity, offerings, and technology to drive efficiency and customer experience.
- →Progressing with a new Sacramento distribution center lease to better serve West Coast customers.
- →Expansion of Actinium-225 production capabilities at Center for Theranostics to support growing demand for targeted cancer therapies.
- →Continued investments in technology and core distribution footprint to support growth across Specialty and other businesses.
- →Focused SG&A investments, particularly in technology and team, to position for future growth while being purposeful and disciplined.
- →Potential bolt-on acquisitions in Specialty areas such as autoimmune and urology, pursued with discipline at the right timing and price.
💰 Fundraising & Capital Structure
No information- →There is no direct mention of new fundraising through debt or equity in the provided pages.
- →The company increased its outlook for interest and other expenses to approximately $340 million (up from $325 million) due to Q3 adjustments, mostly offset in tax and net neutral to the enterprise (Page 4).
- →Share repurchase activity is ongoing, with $1 billion repurchased fiscal year-to-date, exceeding the baseline target by $250 million (Page 2).
- →The company emphasizes disciplined capital allocation and confidence in cash flow generation, with raised adjusted free cash flow guidance to $3.3 billion - $3.7 billion (Page 4).
- →No specific plans or commentary about raising new debt or equity funding were disclosed in the included transcript portions.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
Frequently Asked Questions
What were Cardinal Health, Inc. Q2 FY26 results?
- Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7). - Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth.
What is Cardinal Health, Inc. share price analysis?
Cardinal Health, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 30.6 with a market cap of $46,806. Investors should review the full earnings analysis for detailed insights.
Is Cardinal Health, Inc. planning capital expenditure?
- Investing in infrastructure, technology, and people to improve core Pharma segment, including automation and productivity initiatives in distribution centers.
Keep Cardinal Health, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.